Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain

被引:115
作者
Giesinger, Johannes M. [1 ]
Kuijpers, Wilma [1 ]
Young, Teresa [2 ]
Tomaszewski, Krzysztof A. [3 ]
Friend, Elizabeth [4 ]
Zabernigg, August [5 ]
Holzner, Bernhard [6 ]
Aaronson, Neil K. [1 ]
机构
[1] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Mt Vernon Canc Ctr, Lynda Jackson Macmillan Ctr, Rickmansworth Rd, Northwood HA6 2RN, Middx, England
[3] Jagiellonian Univ, Coll Med, Dept Anat, Krakow, Poland
[4] Basingstoke & North Hampshire Hosp, Ark Ctr, Hepatobiliary Res, Aldermaston Rd, Basingstoke RG24 9NA, Hants, England
[5] Kufstein Cty Hosp, Dept Internal Med, Endach 27, A-6330 Kufstein, Austria
[6] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, Anichstr 35, A-6020 Innsbruck, Austria
基金
奥地利科学基金会;
关键词
Threshold for clinical importance; EORTC QLQ-C30; Patient-reported outcomes; Quality of life; Cancer; QUALITY-OF-LIFE; MALIGNANT-PLEURAL-MESOTHELIOMA; NATIONAL-CANCER-INSTITUTE; RANDOMIZED PHASE-III; SCORES; CARE; IMPROVEMENT; CISPLATIN; SYMPTOMS; TRIAL;
D O I
10.1186/s12955-016-0489-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The EORTC QLQ-C30 is one of the most widely used quality of life questionnaires in cancer research. Availability of thresholds for clinical importance for the individual questionnaire domains could help to increase its interpretability. The aim of our study was to identify thresholds for clinical importance for four EORTC QLQ-C30 scales: Physical Functioning (PF), Emotional Functioning (EF), Pain (PA) and Fatigue (FA). Methods: We recruited adult cancer patients from Austria, the Netherlands, Poland and the UK. No restrictions were placed on diagnosis or type or stage of treatment. Patients completed the QLQ-C30 and three anchor items reflecting potential attributes of clinically important levels of PF, EF, PA and FA. We merged the anchor items assessing perceived burden, limitations in daily activities and need for help into a dichotomous external criterion to estimate thresholds for clinical importance using Receiver Operator Characteristic (ROC) analysis. Results: In our sample of 548 cancer patients (mean age 60.6 years; 54 % female), the QLQ-C30 scales showed high diagnostic accuracy in identifying patients reporting burden, limitations and/or need for help related to PF, EF, PA and FA. All areas under the curve were above 0.86. Conclusions: We were able to estimate thresholds for clinical importance for four QLQ-C30 scales. When used in daily clinical practice, these thresholds can help to identify patients with clinically important problems requiring further exploration and possibly intervention by health care professionals.
引用
收藏
页数:8
相关论文
共 22 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   The Missing Voice of Patients in Drug-Safety Reporting [J].
Basch, Ethan .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869
[3]   Short-term treatment-related symptoms and quality of life: Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study [J].
Bottomley, A ;
Gaafa, R ;
Manegold, C ;
Burgers, S ;
Coens, C ;
Legrand, C ;
Vincent, M ;
Giaccone, G ;
Van Meerbeeck, J .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1435-1442
[4]   Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study [J].
Bottomley, A ;
Biganzoli, L ;
Cufer, T ;
Coleman, RE ;
Coens, C ;
Efficace, F ;
Calvert, HA ;
Gamucci, T ;
Twelves, C ;
Fargeot, P ;
Piccart, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2576-2586
[5]   Implementation of Computer-Based Quality-of-Life Monitoring in Brain Tumor Outpatients in Routine Clinical Practice [J].
Erharter, Astrid ;
Giesinger, Johannes ;
Kemmler, Georg ;
Schauer-Maurer, Gabriele ;
Stockhammer, Guenter ;
Muigg, Armin ;
Hutterer, Markus ;
Rumpold, Gerhard ;
Sperner-Unterweger, Barbara ;
Holzner, Bernhard .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2010, 39 (02) :219-229
[6]   Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences [J].
Gulbrandsen, N ;
Hjermstad, MJ ;
Wisloff, F .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (03) :172-180
[7]  
Hosmer D.W., 1989, Applied logistic regression
[8]   Symptoms and problems in a nationally representative sample of advanced cancer patients [J].
Johnsen, A. T. ;
Petersen, M. A. ;
Pedersen, L. ;
Groenvold, M. .
PALLIATIVE MEDICINE, 2009, 23 (06) :491-501
[9]  
King MT, 2011, EXPERT REV PHARM OUT, V11, P171, DOI [10.1586/erp.11.9, 10.1586/ERP.11.9]
[10]   Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer [J].
Klinkhammer-Schalke, M. ;
Koller, M. ;
Steinger, B. ;
Ehret, C. ;
Ernst, B. ;
Wyatt, J. C. ;
Hofstaedter, F. ;
Lorenz, W. .
BRITISH JOURNAL OF CANCER, 2012, 106 (05) :826-838